表紙:医薬品新興国の市場 - 製品種類別 (医薬品/医療)・地域別 (ティアI/ティアII/ティアIII):市場分析・シェア・動向・規模・予測
市場調査レポート
商品コード
737891

医薬品新興国の市場 - 製品種類別 (医薬品/医療)・地域別 (ティアI/ティアII/ティアIII):市場分析・シェア・動向・規模・予測

Pharmerging Market, By Product Types (Pharmaceuticals and Healthcare), By Geography (Tier I, Tier II and Tier III ) - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025

出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 99 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
医薬品新興国の市場 - 製品種類別 (医薬品/医療)・地域別 (ティアI/ティアII/ティアIII):市場分析・シェア・動向・規模・予測
出版日: 2018年07月19日
発行: AnalystView Market Insights
ページ情報: 英文 99 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、医薬品新興国市場 (Pharmerging Market) - 新興国における医薬品の市場 - について分析し、市場の定義や基本構造、主な市場促進・抑制要因、業界の競争力・求心力、市場シェア構造、分野別/ティア (階層) 別の市場動向見通し (過去4年間・今後8年間分)、主要企業のプロファイルなどについて調査しております。

第1章 医薬品新興国市場:概要

第2章 エグゼクティブ・サマリー

第3章 主な市場動向

  • 市場促進要因
    • 促進要因の影響度
  • 市場抑制要因
    • 抑制要因の影響度
  • 市場機会
  • 市場の将来動向

第4章 産業分析

  • ポーターのファイブフォース分析
  • 市場求心力の分析
  • 規制体制の分析

第5章 医薬品新興国の市場環境

  • 市場シェア分析

第6章 医薬品新興国市場:製品種類別分析

  • 概要
  • 医薬品
    • 概要
    • 市場規模の分析・予測、年間成長率 (金額ベース、通算12年間分)
    • 特許薬
    • ジェネリック医薬品
    • 一般薬 (OTC医薬品)
  • 医療
    • 医療機器
    • 体外 (IV) 診断
    • その他

第7章 医薬品新興国市場:地域別分析

  • イントロダクション
  • ティアI市場:中国
    • 概要
    • 市場規模の分析・予測、年間成長率 (金額ベース、通算12年間分)
  • ティアII市場:インド・ロシア・ブラジル・南アフリカ
  • ティアIII市場:トルコ・ポーランド・メキシコ・アルゼンチン・タイ・サウジアラビア

第8章 主要ベンダーの分析

  • Pfizer, Inc.
    • 企業概要
    • SWOT分析
    • 近年の主な動向
  • AstraZeneca
  • Roche
  • GE Healthcare
  • Medtronic

第9章 アナリストの全方位的分析

第10章 付録

図表

List of Tables

  • Table 1 List of Acronyms
  • Table 2 Key Market Facts, 2014 - 2025
  • Table 3 Market Drivers: Impact Analysis
  • Table 4 Market Restraint: Impact Analysis
  • Table 5 Market Opportunity: Impact Analysis
  • Table 6 PEST Analysis
  • Table 7 Porter's Five Forces Analysis
  • Table 8 Company Market Share Analysis
  • Table 9 Global Pharmerging Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • Table 10 Pharmerging Market, by Product Types, 2014 - 2025 (USD Billion)
  • Table 11 Pharmerging Market, by Geography, 2014 - 2025 (USD Billion)
  • Table 12 Tier I Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 13 China Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 14 Tier II Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 15 India Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 16 Russia Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 17 Brazil Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 18 South Africa Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 19 Tier III Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 20 Turkey Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 21 Poland Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 22 Mexico Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 23 Argentina Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 24 Thiland Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 25 Soudi Arabia Pharmerging Market, 2014 - 2025 (USD Billion)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Research Process Flow Chart
  • Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
  • Figure 4 Regulatory Framework Analysis
  • Figure 5 Pharmerging Market, by Product Types, 2014 - 2025 (USD Billion)
  • Figure 6 Pharmerging Market, by Geography, 2014 - 2025 (USD Billion)
目次
Product Code: AV198

Report Hightlights

The Pharmerging market is estimated to represent a global market of USD 543.9 billion by 2017 with growth rate of 15.7%.

Market Dynamics

The pharmerging industry covers the study for developing countries where the use of pharmaceuticals is rapidly growing and is projected to experience strong growth in the future period. Countries such as China, India, Brazil, Russia, and South Africa among others are considered under the research scope. Drug spending in these economies is increasing at a constant rate, making them attractive targets for drug manufacturers to invest in. For instance, as per the International Federation of Pharmaceutical Manufacturers & Associations, pharmerging economies account for around 50% of absolute growth in drug spending every year.

There is a constant rise of people affected by chronic disorders due to the lifestyle changes. The number of cardiovascular, cancer, respiratory and diabetes patients are increasing monumentally. For example, cardiovascular conditions such as strokes, coronary heart disease, rheumatic heart disease, and cardiomyopathy are expected to be the major causes of mortality and morbidity in developing countries across the world. As per the World Health Organization statistics, more than 80% of cardiovascular deaths occur in low to middle-income countries. Additionally, an aging population, higher standards of living and advancement in technologies in the medical sector have led to a sharp increase in life expectancy. As a consequence, longer-lived individuals will create upward pressure on demand for pharmaceuticals & healthcare services. All such facts would in turn open up a new market for healthcare treatment that have traditionally been targeted at developed region patients.

Product Types Takeaway

In terms of product types, the industry is divided into Pharmaceuticals and Healthcare. Pharmaceuticals segment is further categorized as Patented, Generic and Over-the-Counter Therapeutics. In 2017, generic pharmaceuticals recorded USD 198.7 billion and the segment is projected to grow with strong CAGR during the future period. Healthcare segment is bifurcated as Medical Devices, In-Vitro Diagnostics, and others.

Regional Takeaway

Geographically, the industry is broadly categorized into Tier I, Tier II and Tier III economies. Chinese pharmerging market covers under the Tier I category which is considered one amongst the highest revenue generating country. In 2017, this category has captured over 52% of the worldwide market. According to China's Ministry of Finance (MOF), healthcare expenditure in the country has increased by 10% in 2016. Due to this fact, out-of-pocket spending for healthcare needs in China has decreased, as the penetration of insurance has increased. As of 2015, almost 95.0% of the population is enrolled in at least one public health insurance scheme.

Global Pharmerging Market, by Region, 2017 vs 2025

Tier II category include a detailed study for BRICS countries (except China) such as India, Russia, Brazil and South Africa. India and Brazil collectively accounted for over 60% revenue share of the countries considered under Tier II economy. As per the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), the national pharmaceutical exports are projected to reach USD 20 million by 2020. The Indian pharmaceutical sector is highly fragmented with the presence of more than 15,000 manufactures. Tier III includes extensive qualitative and quantitative study for Turkey, Poland, Mexico, Argentina, Thailand, and Saudi Arabia. These countries represent a wide range of incomes, and GDP Mexico recorded USD 22.9 billion in 2017 and is projected to grow by over 8% CAGR during the study period.

Key Vendor Takeaway

Companies namely Pfizer, Inc., AstraZeneca, Roche, GE Healthcare, and Medtronic are actively operating in this industry. Attributes such as company overview, financials, product benchmarking and key initiatives were discussed separately. Key players are engaged in strategic collaborations to capture untapped market opportunities. For instance, in July 2017, AstraZeneca collaborated with Merck, Inc. to potential cancer therapeutic, MEK and PARP inhibitors in combination with PD-L1 medicines.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2014 & 2016

Base Year - 2017

Estimated Year - 2018

Projected Year - 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY PRODUCT TYPES

Pharmaceuticals

Patented

Generic

Over-the-Counter

Healthcare

Medical Devices

In-Vitro Diagnostics

Others

MARKET, BY REGION

Tier I

China

Tier II

India

Russia

Brazil

South Africa

Tier III

Turkey

Poland

Mexico

Argentina

Thailand

Saudi Arabia

TABLE OF CONTENTS

1. PHARMERGING MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Key Market Facts
  • 2.2. Geographical Scenario
  • 2.3. Companies in the Market

3. PHARMERGING KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. PHARMERGING INDUSTRY STUDY

  • 4.1. Porter's Analysis
  • 4.2. Market Attractiveness Analysis
  • 4.3. Regulatory Framework Analysis

5. PHARMERGING MARKET LANDSCAPE

  • 5.1. Market Share Analysis

6. PHARMERGING MARKET - BY PRODUCT TYPES

  • 6.1. Overview
  • 6.2. Pharmaceuticals
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.2.3. Patented
    • 6.2.3.1. Overview
    • 6.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.2.4. Generic
    • 6.2.4.1. Overview
    • 6.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.2.5. Over-the-Counter
    • 6.2.5.1. Overview
    • 6.2.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.3. Healthcare
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.3.3. Medical Devices
    • 6.3.3.1. Overview
    • 6.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.3.4. In-Vitro Diagnostics
    • 6.3.4.1. Overview
    • 6.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.3.5. Others
    • 6.3.5.1. Overview
    • 6.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

7. PHARMERGING MARKET- BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. Tier I
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.2.3. China
    • 7.2.3.1. Overview
    • 7.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.3. Tier II
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.3. India
    • 7.3.3.1. Overview
    • 7.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.4. Russia
    • 7.3.4.1. Overview
    • 7.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.5. Brazil
    • 7.3.5.1. Overview
    • 7.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.6. South Africa
    • 7.3.6.1. Overview
    • 7.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.4. Tier III
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.3. Turkey
    • 7.4.3.1. Overview
    • 7.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.4. Poland
    • 7.4.4.1. Overview
    • 7.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.5. Mexico
    • 7.4.5.1. Overview
    • 7.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.6. Argentina
    • 7.4.6.1. Overview
    • 7.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.7. Thailand
    • 7.4.7.1. Overview
    • 7.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.8. Saudi Arabia
    • 7.4.8.1. Overview
    • 7.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

8. KEY VENDOR ANALYSIS

  • 8.1. Pfizer, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. SWOT Analysis
    • 8.1.3. Key Developments
  • 8.2. AstraZeneca
    • 8.2.1. Company Overview
    • 8.2.2. SWOT Analysis
    • 8.2.3. Key Developments
  • 8.3. Roche
    • 8.3.1. Company Overview
    • 8.3.2. SWOT Analysis
    • 8.3.3. Key Developments
  • 8.4. GE Healthcare
    • 8.4.1. Company Overview
    • 8.4.2. SWOT Analysis
    • 8.4.3. Key Developments
  • 8.5. Medtronic
    • 8.5.1. Company Overview
    • 8.5.2. SWOT Analysis
    • 8.5.3. Key Developments

Client can request additional company profiling as per specific requirements

9. 360 DEGREE ANALYSTVIEW

10. APPENDIX

  • 10.1. Research Methodology
  • 10.2. Abbreviations
  • 10.3. Disclaimer
  • 10.4. Contact Us